Show notes
Stéphane Bancel has been CEO of Moderna since 2011, but it’s almost as if he's led three different companies in the past five years.
First came the pandemic sprint: A biotech with no commercial products became a household name, manufacturing a billion vaccine doses in 2021 and generating roughly $18 billion in annual sales. Then, the descent. As demand for COVID shots collapsed, revenue fell roughly 90%, its stock price plunged, and Bancel had to cut thousands of jobs.
Now comes another turn. Positive results from a melanoma trial with Merck have sent Moderna's stock sharply higher over…

